Suven Life Sciences Ltd Directors Report

To the Members of Suven Life Sciences Limited

Your Companys Board of Directors has pleasure in presenting this 37^th Annual Report together with Ind AS compliant Audited Financial Statements of the Company for the financial year ended 31^st March, 2026.

Financial Summary

	Standalone	Consolidated
Particulars	Financial Year 2025-26	Financial Year 2024-25	Financial Year 2025-26	Financial Year 2024-25
Income
Revenue from operations	711.47	665.58	711.47	665.58
Other income	1,391.05	1,072.59	1,393.01	1,089.69
Total Income	2,102.52	1,738.17	2,104.48	1,755.27
Expenses
R & D Expenses	2,797.24	3,043.16	24,818.81	14,396.18
Operating expenditure	4,214.43	2,816.16	4,342.95	2,846.76
Depreciation and amortisation	561.35	582.17	561.35	582.17
Total Expenses	7,573.02	6,441.49	29,723.11	17,825.11
Profit before finance costs and tax	(5,470.50)	(4,703.32)	(27,618.63)	(16,069.84)
Finance cost	15.78	4.66	15.78	4.66
Profit/(Loss) before Exceptional Items, Tax	(5,486.28)	(4,707.98)	(27,634.41)	(16,074.50)
Exceptional Items	-	-	-	-
Profit/(Loss) before tax	(5,486.28)	(4,707.98)	(27,634.41)	(16,074.50)
Tax Expense/Tax of ea rlier years	-	-	-	-
Profit/(Loss) for the year	(5,486.28)	(4,707.98)	(27,634.41)	(16,074.50)
Other Comprehensive Income
-Items that will not be reclassified to profit or loss	(22.19)	(5.99)	(22.19)	(5.99)
-Income tax relating to items that will not be reclassified to profit or loss	-	-	(96.20)	(52.34)
Total Other Comprehensive Income	(22.19)	(5.99)	(118.39)	(58.33)
Total Comprehensive Income	(5,508.47)	(4,713.97)	(27,752.80)	(16,132.83)
Retained earnings - opening balance	8,628.59	13,342.56	(60,067.33)	(43,986.84)
Add: Profit/(Loss) for the year	(5,508.47)	(4,713.97)	(27,656.60)	(16,080.49)
Retained earnings - closing balance	3,120.12	8,628.59	(87,723.93)	(60,067.33)

The state of the companys affairs

During the year under review. Company continued to advance its innovation on discovering and developing novel pharmaceutical products, for central nervous system ("CNS") disorders using G Protein-Coupled Receptor targets. Companys focus has been on discovery and development of innovative molecules targeting diseases and areas, which has undiscovered medical treatment opportunities.

Company focuses on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimers disease (AD), Sleep disorders. Major depressive disorders (MDD), Parkinsons disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical-stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimers type (Phase 3 study reaching 76% of patient enrollment); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (After successful completion of Phase 2 study for EDS, initiated Phase 3 study for EDS with and without Cataplexy); Ropanicant (SUVN-911) for MDD (After successful Phase 2a Open Label study, the Placebo-controlled Phase 2b study was completed and expecting for final outcome); Usmarapride (SUVN-D4010) for cognitive disorders (Phase 2 study in planning), SUVN-16107 for cognitive disorders (Phase 1 study completed and planning for next phase). In addition to these clinical assets, we have 8 projects in research pipeline across multiple potential indications. Suven owns all intellectual property rights for its assets in all major markets.

During the year under review,your company has spent Rs.2,797.24 Lakhs (standalone basis) on Research & Development of drug discovery molecules and will continue to spend in the years to come. Your Company reported a loss of Rs.(5,486.28) Lakhs for the financial year 2025-26. The Earnings per Share (EPS) of your Company is Rs.(2.41) per share in fiscal 2025-26 from the previous year EPS of Rs.(2.16) per share in fiscal 2024-25. Your Companys standalone revenue from operations for the Financial Year 2025-26 is T711.47 Lakhs. The consolidated revenue from operations for the Financial Year 2025-26 remained the same as that of standalone revenue. The consolidated loss incurred Rs.(27,634.41) Lakhs are mainly due to clinical development expenditure incurred by Suven Neurosciences, Inc., on various molecules in the clinical development programs.

The consolidated financial statements of the Company prepared in accordance with Indian Accounting Standards as specified in the Companies (Indian Accounting Standards) Rules, 2015, form part of the Annual Report.

Research and Development

During the year, your company has spent Rs.24,818.81 Lakhs (consolidated basis) on innovative R&D in CNS therapies. Suven has 5 clinical stage compounds, ongoing phase 3 study on Masupirdine (SUVN-502) on Agitation in Alzheimers type patients, completed Phase 2 study and initiated Phase 3 study on Samelisant (SUVN-G3031) on Narcolepsy (excessive day time sleep disorder with and without cataplexy), completed

Phase 2 study on Ropanicant (SUVN-911 and waiting for results), ready for phase 2 study on Usmarapride (SUVN-D4010) and SUVN-16107 (completed phase 1 study and planning for next phase).

In addition to these clinical assets, we have 8 projects in research pipeline across multiple potential indications.

The Company also regularly secures various product patents across the world as part of Research & Development of the Company to secure its discovery related innovation. The details on patent updates could be accessed at Companys website http://www.suven.com/Patentupdates.aspx.

Dividend

In view of the losses, the Board of Directors has not recommended any dividend for the year under review.

Transfer to Reserves

The Company has not transferred any amount to the general reserve during the current financial year.

Preferential Issue

Pursuant to the approval of the Board of Directors at its meeting held on May 13, 2025, and the approval of the members of the Company at the Extra-Ordinary General Meeting (EGM) held on June 05, 2025, the Company allotted 6,40,02,999 warrants on July 03, 2025, on a preferential basis, to a promoter group entity and certain identified non-promoter persons/entities at an issue price of Rs.134/- per warrant. Each warrant is convertible into one fully paid-up equity share of Rs.1/- each of the Company. The allotment was made upon receipt of 25% of the issue price (i.e., T33.50 per warrant) as warrant subscription money, in accordance with the provisions of Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The balance 75% of the issue price (i.e., T100.50 per warrant) is payable at any time within 18 months from the date of allotment of warrants.

As on the date of this Report, the Company has allotted 4,54,32,866 fully paid-up equity shares pursuant to the conversion of an equal number of warrants in accordance with the terms of the offer letter issued to the allottees pursuant to the preferential issue. The details of the allotments are provided in the table below:

Financial Year	Date of Allotment	No. of equity shares allotted
2025-2026	July 16, 2025	91,86,490
	January 29, 2026	44,77,612
	March 06, 2026	3,17,68,764

The details of utilisation of funds so received under the Preferential Issue is given hereunder:-

Particulars	Amount ( Rs. in lakhs)
Funds raised	85,764.02*
Amount utilised up to March 31,2026	26,068.64
Unutilised amount	59,695.38

* Out of the issue proceeds of Rs.85,764.02 lakhs, Rs.9,331.50 lakhs are yet to be received from some of the warrant holders.

The Board of Directors confirms thatthere has been no deviation orvariation in the utilisation of proceeds raised by the Company from the objects stated in the relevant offer document (Private Placement Offer cum Application Letter dated June 20, 2025)/ explanatory statement to the EGM Notice dated May 13,2025.

Share Capital

During the year under review, the members of the Company at their Extra-Ordinary General Meeting held on June 05, 2025 approved the increase in Authorised Share Capital from Rs.30,00,00,000/- (Rupees Thirty Crore) divided into 30,00,00,000 (Thirty Crore) Equity Shares of Rs.1/- (Rupees One) each to Rs.50,00,00,000/- (Rupees Fifty Crore) divided into 50,00,00,000 (Fifty Crore) Equity Shares of Rs.1/- (Rupees Ten) each.

During the year under review, the Company has allotted 4,54,32,866 equity shares of Rs.1/- each upon the conversion of warrants issued on preferential basis. Further, the Company allotted 2,14,000 equity shares of Rs.1/- each pursuant to exercise of vested stock options under the Suven Life Employee Stock Option Scheme 2020 by eligible employees of the Company.

As a result, the paid-up equity shares capital of the Company as on March 31,2026 stands increased from Rs.2180.74 Lakhs to T2637.21 lakhs.

Annual Return

Pursuant to sub-section 3(a) of Section 134 and sub-section (3) of Section 92 of the Companies Act 2013, read with Rule 12 of the Companies (Management and Administration) Rules, 2014 the Annual Return as at March 31, 2026 can be accessed at Companys website http://www.suven.com/annualreports.aspx

Number of Meetingsof the Board and Audit Committee

During the year under review. Seven Board Meetings were convened and held and Four Audit Committee Meetings were convened and held. The details of Board meetings and Audit Committee meetings are presented in the Corporate Governance report, which forms part of this Annual Report.

The Audit Committee composed of all independent directors. Shri Santanu Mukherjee is the Chairperson of the Audit Committee and Dr. Vajja Sambasiva Rao, Smt. J.A.S. Padmaja are members of the Audit Committee. The time gap between the said meetings was within the period prescribed under the provisions of the Companies Act, 2013 and the SEBI guidelines thereof.

Directors Responsibility Statement

Your Directors state that:

(a) The applicable accounting standards have been followed in the preparation of the Annual Accounts.

(b) Such accounting policies have been selected and applied consistently and judgments and estimates made when required that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period.

(c) Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.

(d) The Directors have prepared the Annual Accounts on a going concern basis.

(e) Proper internal financial controls were in place to be followed by the Company and that the financial controls were adequate and were operating effectively.

(f) Proper systems devised to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

Policy on Nomination & Remuneration

The Board has, on the recommendation of the Nomination & Remuneration Committee framed a policy for selection and appointment of Directors, Key Managerial Personnel, Senior Management and their remuneration, specifying criteria for evaluation of performance and process. The Remuneration Policy is stated in the Corporate Governance Report and also available at Company website http://www.suven.com/ policiesdocuments.aspx.

Dividend Distribution Policy

The Board has adopted a suitable Policy for Dividend Distribution as per the requirements of SEBI Guidelines. The policy is stated in the Annual Reportand has been uploaded on the Companys website and can be accessed at http://www.suven.com/ policiesdocuments.aspx.

Particulars of Loans, Guarantees or Investments

Details of investments made are furnished in the Standalone Financial Statement which can be referred at Note No. 6 of the Standalone Financial Statement.

The Company did not give any Loans, or provided Guarantees or any security during the year under the provisions of Section 186 of the Companies Act, 2013.

Subsidiary companies

Your Company has one international wholly owned subsidiary company i.e. Suven Neurosciences, Inc. The consolidated financial statements of the Company are prepared in accordance with Indian Accounting Standards as specified in the Companies (Indian Accounting Standards) Rules, 2015, form part of the annual report.

Pursuant to the provisions of Section 129(3) of the Companies Act, 2013, a statement containing salient features of financial statements of subsidiary in Form No. AOC-1 is attached to the financial statements of the Company. Further, pursuant to the provisions of Section 136 of the Act, the separate audited financial statements in respect of the subsidiary company shall be kept open for inspection at the Registered Office of the Company during working hours for a period of 21 days before the date of the Annual General Meeting. Your Company will also make available these documents upon request by any Member of the Company interested in obtaining the same or it can be also accessed on the website of your Company at http:// www.suven.com/subsidiaryaccounts.aspx.

Related Party Transactions

The Particulars of contracts orarrangements with related parties referred to in sub-section (1) of section 188 in the prescribed Form AOC-2 pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014, forms part of this report as "Annexure - A".

The Board has approved a policy for related party transactions which has been uploaded on the Companys website, http:// www.suven.com/policiesdocuments.aspx

Material Changes and Commitments Affecting Financial Position of the Company

There have been no material changes and commitments affecting the financial position of the Company between the end of the financial year of the Company and date of this Report i.e. 13^th May, 2026. There has been no change in the nature of business of the Company.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

The information on conservation of energy, technology absorption, foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule, 8 of the Companies (Accounts) Rules, 2014, forms part of this report as "Annexure - B".

Risk Management Policy

Business risks are inevitable for any business enterprise. Suven is an IP creating and protecting company, strictly adheres to and harmonise with the global patent regime. The Company through its Risk Management policy identifies the various risks and challenges, internally as well as externally and takes appropriate measures with timely actions to mitigate risk. Risk management committee oversee and advise on current risk exposures of the company and future risk strategies and also recommend the Board about riskassessment and minimisation procedures. The risk management procedure is reviewed by the Risk Management Committee and Board of Directors periodically. Risk Management committee also reviewed the Enterprise Risk Management Framework of the Company which is developed based on the Risk Management policy of the Company. The audit committee has additional oversight in the area of financial risks and controls. To ensure the mitigation of risk the Company manages monitors and reports on the principal risks and uncertainties that can impact its ability to achieve its strategic objectives.

Corporate Social Responsibility

In compliance with Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules 2014, the Company has established Corporate Social Responsibility (CSR) Committee composed of Dr.Vajja Sambasiva Rao as Chairperson, Prof. Seyed E. Flasnain, Shri Venkateswarlu Jasti and Smt. J.A.S. Padmaja as members.

The Company continues to incur losses and not made any profits during three immediately preceding financial years. Therefore, there is no spending obligation of the Company under CSR. Accordingly, the Statement on CSR activities is not applicable. Flowever, the CSR Committee reviewed the other compliance requirements viz. formulating & monitoring the CSR policy, etc. in accordance with the provisions of the law. CSR policy of the Company can be accessed on the Companys website at the link:

http://www.suven.com/corporatesocialresponsibility.aspx

Directors and Key Managerial Personnel

During the year under review, the shareholders of the Company at the Extra-ordinary General Meeting held on 05^th June, 2025, approved the re-appointment of Smt. Sudharani Jasti (DIN: 00277998) as a Whole-time Director and KMP of the Company for a further period of five years commencing from 01^st November, 2025 to 31^st October, 2030, whose office shall be liable to retire by rotation.

In the opinion of the Board, all the Independent Directors possess the integrity, expertise and experience including the proficiency required to be Independent Directors of the Company, fulfill the conditions of independence as specified in the Act and the Listing Regulations and are independent of the management and have also complied with the Code for Independent Directors as prescribed in Schedule IV of the Companies Act, 2013.

Changes in Key Managerial Personnel (KMP)

During the year under review, Mr. Shrenik Soni has resigned from his position of Company Secretary and Compliance Officer with effect from end of working hours of January 30, 2026. The Board of Directors in its meeting held on 29^th January, 2026 had on the basis of recommendations of Nomination and Remuneration Committee, appointed Ms. K. Sangeetha Laxmi (M. No. A40736) as Company Secretary and Compliance Officer w.e.f. 02^nd February, 2026.

Except as stated above, the Company did not appoint any Director or Key Managerial Personnel during the year under review. None of the Director or other Key Managerial Personnel has resigned during the year under review.

Declaration by Independent Directors:

All independent directors of the Company have given declarations under Section 149(7) of the Companies Act, 2013 confirming that they meet the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 and Regulation 25 of SEBI LODR Regulations and also affirmed compliance with Code ofconductas required under Regulation 26(3) of the SEBI LODR Regulations.

Directors Retiring by Rotation

In accordance with the provisions of the Companies Act, 2013, Prof. Seyed E. Hasnain, Non-Executive Director (DIN: 02205199) of the Company retires by rotation at the ensuing Annual General Meeting and being eligible, offers himself for re-appointment.

The brief profile(s) of the director(s) seeking appointment/ re-appointment at the ensuing Annual General Meeting are presented in the Annual Report.

Performance Evaluation of the Board

Pursuant to the provisions of the Companies Act, 2013 and as per the SEBI (LODR) Regulations, 2015, the Board has carried out an annual performance evaluation of its own performance, the directors individually as well as the evaluation of the working of its committees. The Independent Directors separately carried out evaluation of Chairperson, Non-Independent Directors and Board as a whole. The performance of each Committee was evaluated by the Board, based on views received from respective Committee Members. The overall performance evaluation of the Individual Director was reviewed by the Chairperson of the Board and feedback was given to Directors. The manner in which the evaluation has been carried out has been explained in the Corporate Governance Report.

Deposits

During FY 2025-26, the Company has not accepted any fixed deposits, and, as such, no amount on account of principal or interest on deposits was outstanding as on the date of the balance sheet.

Internal Financial Control Systemsand their Adequacy

The Company has a comprehensive system of Internal Controls for effective conduct of business and ensure reliability of financial reporting. Your Company has laid down set of standards which enables to implement internal financial control across the organisation and ensure thatthe same are adequate and operating effectively (1) to provide reasonable assurances that: transactions are executed in conformity with generally accepted accounting principles/standards or any other criteria applicable to such statements, (2) to maintain accountability for assets; access to assets is permitted only in accordance with managements general or specific authorisation and the maintenance of records that are in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; and (3) Provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use or disposition of the assets that could have a material effect on the financial statements. The Audit Committee of the Board reviews reports submitted by the independent internal auditors and monitors the functioning of the system.

Vigil Mechanism

The Company promotes ethical behavior in all its business activities. Towards this, the Company has adopted a policy on Vigil Mechanism and Whistle Blower to deal with instance of fraud and mismanagement, if any. The details of the Whistle Blower Policy is explained in the Corporate Governance Report and also posted on the website of the Company http://www.suven.com/policiesdocuments.aspx

Particulars of Employees and Remuneration

The information required under Section 197(12) of the Act read with Rule 5 ofthe Companies (Appointmentand Remuneration of Managerial Personnel) Rules, 2014, forms part of this report as "Annexure - C".

Corporate Governance

A detailed Report on Corporate Governance prepared in substantial compliance with the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, together with the Certificate issued by Practicing Company Secretary regarding the compliance of conditions of corporate governance, is presented in a separate section forming part of this Annual Report.

Managements Discussion and Analysis

Managements Discussion and Analysis Report for the year under review, as stipulated under Regulation 34 of the SEBI (LODR) Regulations, 2015, is presented in a separate section forming part of this Annual Report.

AUDITORS Statutory Auditors

Pursuant to the provisions of Section 139 of the Companies Act, 2013 and the Rules framed thereunder the Company in its Annual General Meeting (AGM) held on 04^th August 2022 has appointed M/s. KARVY&Co., Chartered Accountants (Firm Registration No. 001757S), as statutory auditors of the Company for a period of five years i.e. from the conclusion of the 33^,d Annual General Meeting till the conclusion of the 38^th Annual General Meeting to be held in the year 2027. The Report of the Statutory Auditors does not contain any qualifications, reservation or adverse remark except one comment on audit trail.

The Board notes the auditors comment regarding the absence of an audit trail feature for Property, Plant and Equipment records. This was due to the relocation of lab operations and the ongoing migration to an upgraded record management system during the year. The Company has initiated necessary steps to implement a system-enabled audit trail to ensure compliant and robust record-keeping going forward.

Secretarial Auditors

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, and Regulation 24A of SEBI (LODR) Regulations, 2015, M/s. DVM & Associates LLP, (Firm Registration No. L2017KR002100) Company Secretaries, was appointed as the Secretarial Auditors of the Company, for a term of 5 (five) years commencing from Financial Year 2025-26 to 2029-30, at the 36^th AGM held on 22^nd August, 2025.

The Secretarial Audit Report for the financial year ended March 31, 2026 forms part of this report as "Annexure - D". The Secretarial Audit Report does not contain any qualifications, reservation or adverse remark except one comment on Regulation 19 of the SEBI LODR Regulations.

The Board notes the auditors comment on the penalty levied by the Stock Exchanges for prior period for non-compliance under Regulation 19 of the SEBI (LODR) Regulations. Based on the Companys detailed representations, BSE has granted a waiver, while the application with NSE is under consideration. The Board confirms that necessary corrective measures have since been implemented to ensure continued compliance.

Cost records & Audit

During the year under review in terms of Cost (Records and Audit) Amendment Rules, 2014 dated 31^st December 2014 issued by the Central Government, the requirement of Cost Audit is not applicable to the Company.

The Company is maintaining such accounts and record as specified by the Central Government and as applicable to the Company under sub-section (1) of section 148 of the Companies Act, 2013.

Employees Stock Option Scheme

The Company granted share-based benefits to eligible employees with a view to attracting and retaining the best talent, encouraging employees to align individual performances with Company objectives, and promoting increased participation by them in future growth of the Company.

Suven Life Employee Stock Option Scheme 2020 ("SLSL ESOP 2020")

On September 17, 2020, pursuant to approval by the shareholders in the AGM, the Board has been authorised to introduce, offer, issue and provide share-based incentives to eligible employees of the Company and its subsidiaries under the SLSL ESOP 2020 scheme. In terms of the scheme the total number of options to be granted are 10,00,000 of face value of Rs.1/- each.

The Nomination and Remuneration Committee (NRC) has granted 345000 options under the SLSL ESOP 2020 scheme during the year ended 31^st March, 2026. The granted options shall vest in tranches as decided by the NRC. Further, the total number of equity shares to be allotted to the employees of the Company and its subsidiaries under the SLSL ESOP 2020 does not cumulatively exceed 1% of the issued capital.

The SLSL ESOP 2020 is in compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, as amended and there has been no material change to the plan/ scheme during the fiscal. Employee Compensation Expenses (Share based payment expenses) for the year ended March 31, 2026, is Rs.178.69 Lakhs, as given in Note No. 18 of standalone & consolidated financial statements.

The details of Employees Stock Option Scheme pursuant to Rule 12(9) of Companies (Share Capital and Debentures) Rules, 2014 are provided as "Annexure - E" to this Report. Further, information pursuant to Section 62 of the Companies Act, 2013 read with Rules made thereunder and details of the Scheme as specified in Part F of Schedule - I of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are available on Companys website and may be accessed at www.suven.com.

Business Responsibility and Sustainability Report

The Business Responsibility and Sustainability Report as required under the SEBI Listing Regulations, describing the initiatives taken by the Company from environment, social and governance perspective, forms part of this report as "Annexure - F".

Transfer of Unpaid & Unclaimed Dividend and underlying equity shares to Investor Education and Protection Fund (IEPF)

In accordance with the applicable provisions of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, during the year under review, no equity shares were required to be transferred to the Investor Education and Protection Fund (IEPF) Authority, as there were no shares in respect of which dividends had remained unpaid or unclaimed for seven consecutive years from financial year 2018-2019 onwards.

Disclosure in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

The Company has complied with the provisions relating to the constitution of Internal Complaints Committee as specified under Sexual Flarassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Your Directors further state that during the year under review, there were no cases filed pursuant to the Sexual Flarassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Statement w.r.t. compliance with the provisions relating to Maternity Benefits Act, 1961

Your Company is committed to ensuring a safe, supportive, and inclusive workplace for all women employees. All eligible women employees have been extended the benefits under the said Act, including maternity leave, nursing breaks, and other statutory entitlements as prescribed. Your Company has duly complied with the provisions of the Maternity Benefits Act, 1961, as amended from time to time. Your Company continuously strives to maintain a work environment that upholds the rights and well-being of its women workforce in accordance with applicable laws.

General

There are no Companies which become or ceased to be your Companys subsidiaries, joint ventures or associate Companies during the year. The Company has complied with the provisions of all applicable Secretarial Standards issued by the Institute of Company Secretaries of India during the year under review.

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

(i) Details of frauds reported by auditors under sub-section (12) of section 143 other than those which are reportable to the Central Government.

(ii) the details of application made orany proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year along with their status as at the end of the financial year.

(iii) the details of difference between amount of the valuation done atthe time of one-time settlementand the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof.

(iv) There are no significant material orders passed by the Regulators/ Courts, which would impact the going concern status of the Company and its future operations.

Acknowledgements

Your Directors wish to place on record their gratitude to Shareholders for the confidence reposed by them and thank all the shareholders, customers, dealers, suppliers and other business associates for their contribution to your Companys activities. The Directors also wish to place on record their appreciation of the valuable services rendered by the executives, staff and workers of the Company.

Your Directors also thank the Central Government and State Government, the Financial Institutions and Banks for their support during the year and we look forward to its continuance.

For and on behalf of the Board of Directors
	Venkateswarlu Jasti
Place: Flyderabad	Chairman & MD
Date: May 13, 2026	DIN: 00278028